RHEB and cancer: Hyperactivating and recurrent mutations in mTOR that have been associated with cancer appear to cluster to the FAT and KD (Figure 4D), and some have been shown to increase the catalytic activity of mTORC1 [17,37] and/or reduce the threshold for Rheb-induced activation in vitro [17].